Tokyo, July 29 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058623) titled 'A study on the effect of switching prescription drugs to over-the-counter drugs (Switch OTC) on the willingness of allergic rhinitis patients to choose OTC medicines' on July 29.

Study Type: Interventional

Study Design: Basic Design - Parallel Randomization - Randomized Blinding - Open -no one is blinded Control - No treatment

Primary Sponsor: Institute - Graduate School of Health and Welfare, International University of Health and Welfare.

Condition: Condition - Allergic rhinitis Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - The objective of this study is to examine the effects of physician-provided information regarding switch OTC drugs and insurer-provided financial incentives (healthcare points) on the willingness of patients with mild allergic rhinitis to choose OTC medications. Basic objectives2 - Others

Intervention: Interventions/Control_1 - Group 1: No information provided by physicians; cost reduction amount = yen 0 (no discount). Interventions/Control_2 - Group 2: No information provided by physicians; cost reduction amount = yen 1,000.

Eligibility: Age-lower limit - 22 years-old

Gender - Male and Female Key inclusion criteria - Inclusion criteria are as follows: patients with a diagnosis of allergic rhinitis in their each medical claim data between January 1 and March 31 of 2024 or 2025, who are undergoing initial treatment, have mild symptoms, and do not meet any exclusion criteria. Written informed consent must be obtained. Eligible participants must be aged between 22 and 64 years at the time of consent, regardless of sex. Key exclusion criteria - Exclusion criteria are based on the 2024 Guidelines for the Diagnosis and Treatment of Allergic Rhinitis, and include the following: patients with severe or most severe symptoms; patients with moderate symptoms; patients with mild symptoms using additional steroid nasal sprays; patients using medications containing ingredients not available in OTC drugs; and patients using ophthalmic solutions. Target Size - 185

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2025 Year 05 Month 11 Day Date of IRB - 2025 Year 05 Month 11 Day Anticipated trial start date - 2025 Year 08 Month 07 Day Last follow-up date - 2025 Year 08 Month 30 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067035

Disclaimer: Curated by HT Syndication.